Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Liebman

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Therapeutic Advances in Hematology|October 23, 2023
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III studyDavid J Kuter, James B Bussel, Waleed Ghanima, et al.
The Oncologist|September 28, 2017
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)Nicole M Kuderer, Marek S Poniewierski, Eva Culakova, et al.
JNCI Cancer Spectrum|July 31, 2019
Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort StudyDavendra P S Sohal, Nicole M Kuderer, Frances A Shepherd, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
JCI Insight|January 18, 2019
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I Zwicker, Benjamin L Schlechter, Jack D Stopa, et al.
Research and Practice in Thrombosis and Haemostasis|February 4, 2021
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel methodAdam Cuker, Jenny M Despotovic, Rachael F Grace, et al.
Thrombosis and Haemostasis|December 24, 2024
Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP SummitDimpy Modi, Saifur R Chowdhury, Syed Mahamad, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Blood|September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITPEun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2019
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateNigel S Key, Alok A Khorana, Nicole M Kuderer, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Hematology|October 23, 2023
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III studyDavid J Kuter, James B Bussel, Waleed Ghanima, et al.
The Oncologist|September 28, 2017
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)Nicole M Kuderer, Marek S Poniewierski, Eva Culakova, et al.
JNCI Cancer Spectrum|July 31, 2019
Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort StudyDavendra P S Sohal, Nicole M Kuderer, Frances A Shepherd, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
JCI Insight|January 18, 2019
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I Zwicker, Benjamin L Schlechter, Jack D Stopa, et al.
Research and Practice in Thrombosis and Haemostasis|February 4, 2021
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel methodAdam Cuker, Jenny M Despotovic, Rachael F Grace, et al.
Thrombosis and Haemostasis|December 24, 2024
Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP SummitDimpy Modi, Saifur R Chowdhury, Syed Mahamad, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Blood|September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITPEun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2019
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline UpdateNigel S Key, Alok A Khorana, Nicole M Kuderer, et al.
Pageof 7